Introduction
Respiratory viral infections are one of the most important global public health burdens, resulting in millions of hospitalizations worldwide annually (1, 2). Respiratory Syncytial Virus (RSV) is the leading cause of acute lower respiratory tract infections (ALRTI) in children under the age of 2 (3) and adults over 65 (4). RSV-induced disease can range from symptoms similar to the common cold to complex respiratory diseases, such as pneumonia or bronchiolitis, leading to extrapulmonary sequelae in the brain and other tissues (5). During the 1960s, a formalin-inactivated RSV (FI-RSV) vaccine was evaluated in children. Vaccinated individuals exhibited increased disease severity upon subsequent natural RSV infection compared to the controls (6–9). This vaccine-enhanced disease resulted from the failure of the vaccine to elicit either potent neutralizing antibodies or memory CD8+ T cells as well as the induction of a strong inflammatory CD4 T cell response (10–13). Currently, the only treatment option available for RSV is a humanized monoclonal antibody against the RSV F surface protein, known as palivizumab (14). However, its usage is limited to high-risk individuals, such as preterm babies, and infants with congenic diseases (15–17). Due to prolonged concerns about vaccine safety, a better understanding of RSV-induced pathogenesis and the host immune response is needed to aid in the development of safe and effective treatments and vaccines for RSV. This Opinion article examines the various vaccine modalities currently undergoing testing and discusses the advantages and disadvantages of the strategies being employed.
RSV Vaccine Modalities and Lessons From the Host Immune Response
Based on the knowledge gained from the unsuccessful FI-RSV vaccine trial, new vaccine formulations are being developed that promote neutralizing antibodies, induce activated memory and lung-resident CD8+ T cells, and can be administered to different target populations including children, elderly and pregnant women. The most promising vaccine candidates currently being evaluated in humans are live-attenuated, recombinant vector-based, and subunit vaccines.
Live-attenuated vaccines demonstrate favorable benefits including a low risk of causing vaccine-enhanced disease, and they can promote both a humoral and cellular immune response. However, potential drawbacks include conserving the stability of the formulation, and balancing the attenuation of the virus while maintaining replicative activity and immunogenicity in the host (18). Additionally, further studies are needed to assess the safety of live-attenuated vaccines in multiple populations (19). Many live-attenuated vaccines are currently undergoing testing in clinical trials and demonstrate a robust induction of a humoral immune response; however, much less information is known about the cellular immune responses induced by the vaccines. Deletion of the M2-2 protein from the RSV strain A2 (LIDΔM2-2) induced robust serum RSV-specific IgG and neutralizing antibody titers that correlated with lower nasal wash viral titers administered intranasally to seronegative children (20). A similar induction of serum neutralizing antibodies was observed with a cold-passage/stabilized RSV containing several attenuating point mutations as well as deletion of the small hydrophobic (SH) protein (RSVcps2) (21). Finally, preclinical studies of a recombinant BCG vaccine expressing the RSV nucleoprotein (N) demonstrated an effective cellular and humoral immune response in mice (22–25).
Recombinant vector-based vaccines allow the presentation of one or more antigens expressed on a viral vector such as parainfluenza virus type 3 (PIV3) or adenovirus. This allows for natural presentation of the antigen of interest to immune cells. A PIV3 vector expressing the RSV F protein (MEDI-534) demonstrated safety in a Phase 1 study when administered intranasally to young children (26). Interestingly, some discordance was observed in the specificity of the immune response. Sequencing of viral samples suggested that modifications were generated post-vaccination in a number of subjects that promoted a reduction in the expression of the F protein correlating with lower neutralizing antibodies in those individuals (27). A recently developed vaccine composed of a chimpanzee adenovirus viral vector expressing the RSV F, N, and M2-1 proteins (ChAd155-RSV) induced robust neutralizing antibody titers and interferon gamma (IFNγ)-secreting T cells compared to placebo controls (28). ReiThera Srl developed a similar vaccine using a chimpanzee adenovirus (PanAd3) viral vector expressing the RSV F, N, and M2-1 proteins in combination with a modified vaccinia virus Ankara (MVA). Intramuscular and intranasal delivery of the vaccine to healthy adults was well tolerated and induced both RSV-specific antibody titers and RSV-specific CD4 and CD8+ T cells (29–31). Interestingly, other clinical trials using adenovirus have been developed to date (NCT03982199, NCT03636906, among others).
Subunit vaccines are a common vaccine modality; however, some disadvantages are associated with these formulations such as the frequent need to use an adjuvant to increase the immunogenicity. A single dose of an RSV F protein subunit vaccine combined with aluminum hydroxide induced RSV F-specific antibodies that persisted for >180 days post-vaccination (32). Similar results were observed following intramuscular administration to women of child-bearing age, suggesting that maternal immunization with this vaccine candidate could generate lasting antibodies to passively transfer to the fetus during the pregnancy (33). Another vaccine utilizing the RSV F protein demonstrated safety and efficacy in Phase 1 and Phase 2 clinicals trials when administered without an adjuvant, suggesting that a subunit vaccine may induce lasting protection without an added adjuvant (34). Interestingly, formulations using the RSV F protein have failed to provide protection against RSV infection in older adult populations, indicating that subunit vaccines may not be the best candidate for this target population (35).
Many vaccine prototypes are focused on viral surface proteins (36, 37). One of the most common viral targets for antibodies is the RSV fusion (F) protein (38, 39). Vaccine formulations containing the N protein also induce long-lasting neutralizing antibodies and could serve as a novel antiviral target (22, 25). The RSV G protein is involved in the initiation of the virus life cycle and has a potent effect on the regulation of the immune response (36). The SH protein can promote a protective immune response in animal models of RSV through Fc receptor-mediated interactions with macrophages and helping the promotion of long-lasting antibodies (40, 41). Furthermore, other protein targets are currently being or have been evaluated in clinical trials, including the nonstructural protein 2 (NS2) (NCT03596801, NCT03473002) and the M2-2 protein (20, 42). However, independent of the antigen evaluated, the key requirement of any RSV vaccine is the ability to promote a safe, but effective and protective immune response.
On the other hand, another type of vaccine strategy that has provided positive and interesting results in human tests is based on intranasal administration of a novel BLP (bacterium like particle) conjugated to the RSV fusion (F) protein eliciting both mucosal IgA responses and elevated IFN-γ production (43). Since BLP prototype is a promising strategy, more assays to evaluate long-lasting immune response are required.
The choice of administration route is an important decision in vaccine development, with most vaccines being delivered via the sublingual, intramuscular, or intranasal route. Sublingual administration of an RSV G protein vaccine induced enhanced cellular infiltration and pro-inflammatory cytokine production compared to intranasal delivery (37). Similar results were observed when a recombinant RSV attachment (G) protein containing the central regions for both RSV A and B serotypes was administrated either intranasally or sublingually (44). Sublingual delivery enhanced pulmonary eosinophil recruitment and body weight loss, while intranasal administration promoted enhanced IgG and IgA antibodies and lower pro-inflammatory cell recruitment into the lung. Mucosal administration may also induce a high titer of IgA in bronchial alveolar lavage (BAL) fluid and IgG antibodies in serum (44, 45). A murine cytomegalovirus vector expressing the RSV matrix (M) protein induced robust lung-resident memory T cell populations when administered intranasally compared to intraperitoneally, where this population was almost undetectable (46, 47). This suggests that intranasal administration of an RSV vaccine would induce an enhanced CD8+ T cell response, a strong secretion of IgG and IgA antibodies, and decrease the inflammatory state of the lung.
One way to aid in the successful development of an RSV vaccine is to gain a better understanding of the host immune response to the virus and the factors required for long-term immunity. Studies examining the host response during acute infection of infants suggest that the virus elicits a pathogenic Th2 dominant response (10–13). Th2-biased T cells, driven by IL-4, IL-5, and IL-13 cytokines, lead to inflammation and hyperreactivity of the airways (48–51). Other T cell populations, including regulatory T cells (Tregs) and Th17 cells, also play an important role during RSV infection (52). Th17 cells can promote a pro-inflammatory state leading to enhanced neutrophil recruitment and reduced CD8+ T cell activation (53). Tregs are associated with the active recruitment of cytotoxic CD8+ T cells in the lung; however, unbalanced Tregs could promote enhanced lung damage (54, 55). Interestingly, peripheral blood mononuclear cells (PBMCs) from infected children exhibit reduced Tregs compared to age-matched controls (56). Similarly, depletion of Tregs in mice promoted enhanced lung pathology following RSV infection (57, 58). Thus, a successful vaccine should induce a balanced T cell response characterized by Th1-biased T cells as well as Tregs.
The induction of type I IFN are essential for RSV viral clearance. The absence of type I IFN promotes a pro-inflammatory response that helps to induce a lung pathology in both human and murine models of infection (59). The administration of IFN-α in RSV-naïve high-risk infants is associated with a decrease in lung pathology and enhanced viral clearance. However, RSV possesses several evasion mechanisms, and both the NS1 protein and the G protein can suppress the type I IFN response (60). A vaccine that induces a powerful type I IFN secretion within its response could be considered a good candidate against RSV.
CD8+ T cells play a critical role in RSV-clearance (61). Murine studies of RSV demonstrate a protective role for memory CD8+ T cells in promoting viral clearance and providing protection from reinfection (61, 62). Nevertheless, natural RSV infection induces low levels of CD8+ T cells. Thus, it would be advantageous for a vaccine to promote a Th-1 immune response and generate memory CD8+ T cells (23–25). In contrast, CD4+ T cells have a controversial role during RSV infection. Following natural infection, CD4+ T cells can promote a dysbalanced host response that enhances immunopathology. However, adoptive transfer studies in the mouse model also suggest that CD4+ T cells can play a protective role. The induction of a Th-1 polarized immune response that promotes both CD8+ and CD4+ T cells is essential for a vaccine to induce a protective immune response against RSV.
The decline in neutralizing antibodies after the RSV infection is an important factor in the reinfections that occur in children. Several formulations of vaccines seek to induce neutralizing antibodies in high risk populations and maternal antibodies that will be transferred from the mother to the fetus to protect against early RSV infections. Nevertheless, these formulations have been shown to induce antibodies that are short-lived. Interestingly, intranasal vaccines have demonstrated the ability to induce high levels of neutralizing antibodies and also promote the IgA secretion that is directly associated with a protective immune response against RSV (43–45, 59, 63).
Discussion
Severe RSV-induced disease continues to present a major global health burden in high-risk groups such as preterm infants, newborns, elderly populations, and those with many associated comorbidities. There is no licensed vaccine to prevent RSV infections, and the only prophylaxis currently approved by the Food and Drug Administration (FDA) is the monoclonal antibody palivizumab. However, its limited use in high-risk groups (14), as well as the high cost and moderate effectiveness underscore the need for additional options. There remains a critical need to develop safe and effective RSV vaccines and therapeutics to combat RSV disease severity in infants and high-risk populations.
In conclusion a vaccine against RSV that promotes an effective antiviral response must induce a prolonged neutralizing antibody response, Th-1 polarized immunity that promotes both CD8+ and CD4+ T cells, type I IFN secretion and an efficient mucosa immune response.
Statements
Author contributions
JS, LS, and KW wrote and revised the manuscript. GC-M contributed to the revision and editing of the manuscript. SV and AK were the lead investigators and revised the manuscript. All authors contributed to the article and approved the submitted version.
Funding
This research was funded by FONDECYT 1190830, 3190590 and the Millennium Institute on Immunology and Immunotherapy P09/016-F. This work was supported by the Department of Microbiology and Immunology at the University of Iowa (to SV) and the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH, R01AI124093 to SV and T32AI007485 to LS).
Acknowledgments
AK is a Helen C. Levitt visiting professor at the Department of Microbiology and Immunology of the University of Iowa.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1.
BontLChecchiaPAFaurouxBFigueras-AloyJManzoniPPaesBet al. Defining the epidemiology and burden of severe Respiratory Syncytial Virus infection among infants and children in Western Countries. Infect Dis Ther. (2016) 5:271–98. 10.1007/s40121-016-0123-0
2.
ModjarradKGiersingBKaslowDCSmithPGMoorthyVS. WHO consultation on Respiratory Syncytial Virus vaccine development report from a World Health Organization Meeting held on 23–24 March 2015. Vaccine. (2016) 34:190–7. 10.1016/j.vaccine.2015.05.093
3.
NairHNokesDJGessnerBDDheraniMMadhiSASingletonRJet al. Global burden of acute lower respiratory infections due to Respiratory Syncytial Virus in young children: a systematic review and meta-analysis. Lancet. (2010) 375:1545–55. 10.1016/S0140-6736(10)60206-1
4.
FalseyARHennesseyPAFormicaMACoxCWalshEE. Respiratory Syncytial Virus infection in elderly and high-risk adults. N Engl J Med. (2005) 352:1749–59. 10.1056/NEJMoa043951
5.
KrilovLR. Respiratory Syncytial Virus disease: update on treatment and prevention. Exp Rev Anti Infect Ther. (2011) 9:27–32. 10.1586/eri.10.140
6.
KimHWCancholaJGBrandtCDPylesGChanockRMJensenKet al. Respiratory Syncytial Virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. (1969) 89:422–34. 10.1093/oxfordjournals.aje.a120955
7.
ChinJMagoffinRLShearerLASchiebleJHLennetteEH. Field evaluation of a Respiratory Syncytial Virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol. (1969) 89:449–63. 10.1093/oxfordjournals.aje.a120957
8.
FulginitiVAEllerJJSieber OF JoynerJWMinamitaniMMeiklejohnG. Respiratory virus immunization: a field trial of two inactivated respiratory virus vaccines; an aqueous trivalent paratnfluenza virus vaccine and an alum-precipitated Respiratory Syncytial Virus vaccine. Am J Epidemiol. (1969) 89:435–48. 10.1093/oxfordjournals.aje.a120956
9.
KapikianAZMitchellRHChanockRMShvedoffRAStewartCE. An epidemiologic study of altered clinical reactivity to Respiratory Syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol. (1969) 89:405–21. 10.1093/oxfordjournals.aje.a120954
10.
OlsonMRVargaSM. CD8 T cells inhibit Respiratory Syncytial Virus (RSV) vaccine-enhanced disease. J Immunol. (2007) 179:5415–24. 10.4049/jimmunol.179.8.5415
11.
OlsonMRHartwigSMVargaSM. The number of Respiratory Syncytial Virus (RSV)-specific memory CD8 T cells in the lung is critical for their ability to inhibit RSV vaccine-enhanced pulmonary eosinophilia. J Immunol. (2008) 181:7958–68. 10.4049/jimmunol.181.11.7958
12.
KnudsonCJHartwigSMMeyerholzDKVargaSM. RSV vaccine-enhanced disease is orchestrated by the combined actions of distinct CD4 T cell subsets. PLOS Pathog. (2015) 11:e1004757. 10.1371/journal.ppat.1004757
13.
DelgadoMFCovielloSMonsalvoACMelendiGAHernandezJZBatalleJPet al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced Respiratory Syncytial Virus disease. Nat Med. (2009) 15:34–41. 10.1038/nm.1894
14.
VillageEG. Palivizumab, a humanized Respiratory Syncytial Virus monoclonal antibody, reduces hospitalization from Respiratory Syncytial Virus infection in high-risk infants. Pediatrics. (1998) 102:531–7. 10.1542/peds.102.3.531
15.
SubramanianKNSWeismanLERhodesTAriagnoRSánchezPJSteichenJet al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to Respiratory Syncytial Virus in premature infants and infants with bronchopulmonary dysplasia. Pediatr Infect Dis J. (1998) 17:110–5. 10.1097/00006454-199802000-00006
16.
Sáez-LlorensXCastañoENullDSteichenJSánchezPJRamiloOet al. Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to Respiratory Syncytial Virus in premature infants and infants with bronchopulmonary dysplasia. Pediatr Infect Dis J. (1998) 17:787–91. 10.1097/00006454-199809000-00007
17.
VillageEG. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for Respiratory Syncytial Virus infection. Pediatrics. (2014) 134:415–20. 10.1542/peds.2014-1665
18.
KimHWArrobioJOBrandtCDWrightPHodesDChanockRMet al. Safety and antigenicity of temperature sensitive (TS) mutant Respiratory Syncytial Virus (RSV) in infants and children. Pediatrics. (1973) 52:56–63.
19.
MalkinEYogevRAbughaliNSlimanJWangCKZuoFet al. Safety and immunogenicity of a live attenuated RSV vaccine in healthy RSV-seronegative children 5 to 24 months of age. PLoS ONE. (2013) 8:e77104. 10.1371/journal.pone.0077104
20.
McFarlandEJKarronRAMuresanPCunninghamCKValentineMEPerlowskiCet al. Live-attenuated Respiratory Syncytial Virus vaccine candidate with deletion of RNA synthesis regulatory protein M2-2 is highly immunogenic in children. J Infect Dis. (2018) 217:1347–55. 10.1093/infdis/jiy040
21.
BuchholzUJCunninghamCKMuresanPGnanashanmugamDSatoPSiberryGKet al. Live Respiratory Syncytial Virus (RSV) vaccine candidate containing stabilized temperature-sensitivity mutations is highly attenuated in RSV-seronegative infants and children. J Infect Dis. (2018) 217:1338–46. 10.1093/infdis/jiy066
22.
SotoJAGálvezNMSRiveraCAPalavecinoCECéspedesPFRey-JuradoEet al. Recombinant BCG vaccines reduce pneumovirus-caused airway pathology by inducing protective humoral immunity. Front Immunol. (2018) 9:2875. 10.3389/fimmu.2018.02875
23.
BuenoSMGonzalezPACautivoKMMoraJELeivaEDTobarHEet al. Protective T cell immunity against Respiratory Syncytial Virus is efficiently induced by recombinant BCG. Proc Natl Acad Sci USA. (2008) 105:20822–7. 10.1073/pnas.0806244105
24.
CautivoKMBuenoSMCortesCMWozniakARiedelCAKalergisAM. Efficient lung recruitment of Respiratory Syncytial Virus-specific Th1 cells induced by recombinant bacillus calmette-guérin promotes virus clearance and protects from infection. J Immunol. (2010) 185:7633–45. 10.4049/jimmunol.0903452
25.
CéspedesPFRey-JuradoEEspinozaJARiveraCACanedo-MarroquínGBuenoSMet al. A single, low dose of a cGMP recombinant BCG vaccine elicits protective T cell immunity against the human Respiratory Syncytial Virus infection and prevents lung pathology in mice. Vaccine. (2017) 35:757–66. 10.1016/j.vaccine.2016.12.048
26.
GomezMMufsonMADubovskyFKnightlyCZengWLosonskyG. Phase-I study Medi-534, of a live, attenuated intranasal vaccine against Respiratory Syncytial Virus and parainfluenza-3 virus in seropositive children. Pediatr Infect Dis J. (2009) 28:655–8. 10.1097/INF.0b013e318199c3b1
27.
YangC-FWangCKMalkinESchickliJHShambaughCZuoFet al. Implication of Respiratory Syncytial Virus (RSV) F transgene sequence heterogeneity observed in Phase 1 evaluation of MEDI-534, a live attenuated parainfluenza type 3 vectored RSV vaccine. Vaccine. (2013) 31:2822–7. 10.1016/j.vaccine.2013.04.006
28.
CicconiPJonesCSarkarESilva-ReyesLKlenermanPde LaraCet al. First-in-human randomized study to assess the safety and immunogenicity of an investigational Respiratory Syncytial Virus (RSV) vaccine based on chimpanzee-adenovirus-155 viral vector–expressing RSV fusion, nucleocapsid, and antitermination viral proteins. Clin Infect Dis. (2020) 70:2073–81. 10.1093/cid/ciz653
29.
GreenCAScarselliESandeCJThompsonAJde LaraCMTaylorKSet al. Chimpanzee adenovirus– and MVA-vectored Respiratory Syncytial Virus vaccine is safe and immunogenic in adults. Sci Transl Med. (2015) 7:300ra126. 10.1126/scitranslmed.aac5745
30.
GreenCAScarselliEVoyseyMCaponeSVitelliANicosiaAet al. Safety and immunogenicity of novel Respiratory Syncytial Virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 cl. BMJ Open. (2015) 5:e008748. 10.1136/bmjopen-2015-008748
31.
GreenCASandeCJScarselliECaponeSVitelliANicosiaAet al. Novel genetically-modified chimpanzee adenovirus and MVA-vectored Respiratory Syncytial Virus vaccine safely boosts humoral and cellular immunity in healthy older adults. J Infect. (2019) 78:382–92. 10.1016/j.jinf.2019.02.003
32.
Leroux-RoelsGDe BoeverFMaesCNguyenTL-ABakerSGonzalez LopezA. Safety and immunogenicity of a Respiratory Syncytial Virus fusion glycoprotein F subunit vaccine in healthy adults: results of a phase 1, randomized, observer-blind, controlled, dosage-escalation study. Vaccine. (2019) 37:2694–703. 10.1016/j.vaccine.2019.04.011
33.
AugustAGlennGMKpameganEHickmanSPJaniDLuHet al. A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted Respiratory Syncytial Virus F particle vaccine formulations in healthy women of childbearing age. Vaccine. (2017) 35:3749–59. 10.1016/j.vaccine.2017.05.045
34.
SchwarzTFMcPheeRALaunayOLeroux-RoelsGTalliJPicciolatoMet al. Immunogenicity and safety of 3 formulations of a Respiratory Syncytial Virus candidate vaccine in nonpregnant women: a phase 2, randomized trial. J Infect Dis. (2019) 220:1816–25. 10.1093/infdis/jiz395
35.
FalloonJYuJEsserMTVillafanaTYuLDubovskyFet al. An adjuvanted, postfusion F protein–based vaccine did not prevent Respiratory Syncytial Virus illness in older adults. J Infect Dis. (2017) 216:1362–70. 10.1093/infdis/jix503
36.
Boyoglu-BarnumSChirkovaTAndersonLJ. Biology of infection and disease pathogenesis to guide RSV vaccine development. Front Immunol. (2019) 10:1675. 10.3389/fimmu.2019.01675
37.
CheonISKimJYChoiYShimB-SChoiJJungD-I. Sublingual immunization with an RSV G glycoprotein fragment primes IL-17-mediated immunopathology upon Respiratory Syncytial Virus infection. Front Immunol. (2019) 10:567. 10.3389/fimmu.2019.00567
38.
YeXIwuchukwuOPAvadhanulaVAideyanLOMcBrideTJFerlic-StarkLLet al. Antigenic site-specific competitive antibody responses to the fusion protein of Respiratory Syncytial Virus were associated with viral clearance in hematopoietic cell transplantation adults. Front Immunol. (2019) 10:706. 10.3389/fimmu.2019.00706
39.
ArandaSSPolackFP. Prevention of pediatric Respiratory Syncytial Virus lower respiratory tract illness: perspectives for the next decade. Front Immunol. (2019) 10:1006. 10.3389/fimmu.2019.01006
40.
SchepensBSedeynKVande GinsteLDe BaetsSSchotsaertMRooseKet al. Protection and mechanism of action of a novel human Respiratory Syncytial Virus vaccine candidate based on the extracellular domain of small hydrophobic protein. EMBO Mol Med. (2014) 6:1436–54. 10.15252/emmm.201404005
41.
LangleyJMMacDonaldLDWeirGMMacKinnon-CameronDYeLMcNeilSet al. A Respiratory Syncytial Virus vaccine based on the small hydrophobic protein ectodomain presented with a novel lipid-based formulation is highly immunogenic and safe in adults: a first-in-humans study. J Infect Dis. (2018) 218:378–87. 10.1093/infdis/jiy177
42.
KarronRALuongoCThumarBLoehrKMEnglundJACollinsPLet al. A gene deletion that up-regulates viral gene expression yields an attenuated RSV vaccine with improved antibody responses in children. Sci Transl Med. (2015) 7:312ra175. 10.1126/scitranslmed.aac8463
43.
AscoughSVlachantoniIKalyanMHaijemaB-JWallin-WeberSDijkstra-TiekstraMet al. Local and systemic immunity against Respiratory Syncytial Virus induced by a novel intranasal vaccine. A randomized, double-blind, placebo-controlled clinical trial. Am J Respir Crit Care Med. (2019) 200:481–92. 10.1164/rccm.201810-1921OC
44.
LeeJ-YChangJ. Universal vaccine against Respiratory Syncytial Virus A and B subtypes. PLoS ONE. (2017) 12:e0175384. 10.1371/journal.pone.0175384
45.
YangKVargaSM. Mucosal vaccines against Respiratory Syncytial Virus. Curr Opin Virol. (2014) 6:78–84. 10.1016/j.coviro.2014.03.009
46.
MorabitoKMRuckwardtTRRedwoodAJMoinSMPriceDAGrahamBS. Intranasal administration of RSV antigen-expressing MCMV elicits robust tissue-resident effector and effector memory CD8+ T cells in the lung. Mucosal Immunol. (2017) 10:545–54. 10.1038/mi.2016.48
47.
LiHCallahanCCitronMWenZTouchSMonslowMAet al. Respiratory Syncytial Virus elicits enriched CD8+ T lymphocyte responses in lung compared with blood in African green monkeys. PLoS ONE. (2017) 12:e0187642. 10.1371/journal.pone.0187642
48.
TregoningJSYamaguchiYHarkerJWangBOpenshawPJM. The role of T cells in the enhancement of Respiratory Syncytial Virus infection severity during adult reinfection of neonatally sensitized mice. J Virol. (2008) 82:4115–24. 10.1128/JVI.02313-07
49.
CulleyFJPollottJOpenshawPJM. Age at first viral infection determines the pattern of T cell–mediated disease during reinfection in adulthood. J Exp Med. (2002) 196:1381–6. 10.1084/jem.20020943
50.
YouDMarrNSaraviaJShresthaBLeeGITurveySEet al. IL-4Rα on CD4 + T cells plays a pathogenic role in Respiratory Syncytial Virus reinfection in mice infected initially as neonates. J Leukoc Biol. (2013) 93:933–42. 10.1189/jlb.1012498
51.
ShresthaBYouDSaraviaJSiefkerDTJaligamaSLeeGIet al. IL-4Rα on dendritic cells in neonates and Th2 immunopathology in Respiratory Syncytial Virus infection. J Leukoc Biol. (2017) 102:153–61. 10.1189/jlb.4A1216-536R
52.
LukacsNWSmitJJMukherjeeSMorrisSBNunezGLindellDM. Respiratory virus-induced TLR7 activation controls IL-17–associated increased mucus via IL-23 regulation. J Immunol. (2010) 185:2231–9. 10.4049/jimmunol.1000733
53.
MukherjeeSLindellDMBerlinAAMorrisSBShanleyTPHershensonMBet al. IL-17–induced pulmonary pathogenesis during respiratory viral infection and exacerbation of Allergic Disease. Am J Pathol. (2011) 179:248–58. 10.1016/j.ajpath.2011.03.003
54.
MangodtTCVan HerckMANullensSRametJDe DooyJJJorensPGet al. The role of Th17 and Treg responses in the pathogenesis of RSV infection. Pediatr Res. (2015) 78:483–91. 10.1038/pr.2015.143
55.
OpenshawPJChiuC. Protective and dysregulated T cell immunity in RSV infection. Curr Opin Virol. (2013) 3:468–74. 10.1016/j.coviro.2013.05.005
56.
ChristiaansenAFSyedMATen EyckPPHartwigSMDurairajLKamathSSet al. Altered Treg and cytokine responses in RSV-infected infants. Pediatr Res. (2016) 80:702–9. 10.1038/pr.2016.130
57.
DurantLRMakrisSVoorburgCMLoebbermannJJohanssonCOpenshawPJM. Regulatory T cells prevent Th2 immune responses and pulmonary eosinophilia during Respiratory Syncytial Virus infection in mice. J Virol. (2013) 87:10946–54. 10.1128/JVI.01295-13
58.
FultonRBMeyerholzDKVargaSM. Foxp3 + CD4 regulatory T cells limit pulmonary immunopathology by modulating the CD8 T cell response during Respiratory Syncytial Virus infection. J Immunol. (2010) 185:2382–92. 10.4049/jimmunol.1000423
59.
HijanoDRSiefkerDTShresthaBJaligamaSVuLDTillmanHet al. Type I interferon potentiates IgA immunity to Respiratory Syncytial Virus infection during infancy. Sci Rep. (2018) 8:11034. 10.1038/s41598-018-29456-w
60.
TognarelliEIBuenoSMGonzálezPA. Immune-modulation by the human Respiratory Syncytial Virus: focus on dendritic cells. Front Immunol. (2019) 10:810. 10.3389/fimmu.2019.00810
61.
GrahamBSBuntonLAWrightPFKarzonDT. Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with Respiratory Syncytial Virus in mice. J Clin Invest. (1991) 88:1026–33. 10.1172/JCI115362
62.
SchmidtMEKnudsonCJHartwigSMPeweLLMeyerholzDKLangloisRAet al. Memory CD8 T cells mediate severe immunopathology following Respiratory Syncytial Virus infection. PLOS Pathog. (2018) 14:e1006810. 10.1371/journal.ppat.1006810
63.
SalischNCIzquierdo GilACzapska-CaseyDNVorthorenLSerroyenJTolboomJet al. Adenovectors encoding RSV-F protein induce durable and mucosal immunity in macaques after two intramuscular administrations. NPJ Vaccines. (2019) 4:54. 10.1038/s41541-019-0150-4
Summary
Keywords
Respiratory Syncytial Virus, treatments, vaccines, antibodies, T cells
Citation
Soto JA, Stephens LM, Waldstein KA, Canedo-Marroquín G, Varga SM and Kalergis AM (2020) Current Insights in the Development of Efficacious Vaccines Against RSV. Front. Immunol. 11:1507. doi: 10.3389/fimmu.2020.01507
Received
31 March 2020
Accepted
09 June 2020
Published
17 July 2020
Volume
11 - 2020
Edited by
Xulin Chen, Jinan University, China
Reviewed by
Xuguang Li, Health Canada, Canada
Updates
Copyright
© 2020 Soto, Stephens, Waldstein, Canedo-Marroquín, Varga and Kalergis.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Alexis M. Kalergis akalergis@bio.puc.cl
This article was submitted to Viral Immunology, a section of the journal Frontiers in Immunology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.